***Background.*** Increasing rates of multidrug-resistant (MDR) Enterobacteriaceae (ENT) challenges infection control and antimicrobial stewardship practices. We evaluated the activity of ceftazidime-avibactam (CAZ-AVI), a cephalosporin combined with a serine-β-lactamase (BL) inhibitor displaying activity against ENT, including those producing contemporary BLs.

***Methods.*** 20,709 ENT isolates collected from 2011 to 2013 in 79 hospitals located in all nine USA Census regions were susceptibility (S) tested by CLSI broth microdilution against CAZ-AVI and comparators. CTX-M- and KPC-encoding genes were identified by a microarray based assay and/or reference PCR/sequencing.

***Results.*** Overall CAZ-AVI inhibited 99.9% of isolates at ≤4 µg/mL (CLSI CAZ-S breakpoint) and was only less potent than meropenem (MIC~90~, 0.25 and ≤0.06 µg/mL, respectively). Among 25 isolates displaying CAZ-AVI MICs at \>4 µg/mL, 15 were indole-positive Proteae with MICs of 8-16 µg/mL and 3 *K. pneumoniae* (KPN) producing metallo-BLs (CAZ-AVI MIC, \>32 µg/mL). Against the most prevalent bacterial species, CAZ-AVI inhibited all *E. coli* isolates, 99.9% of KPN and \>99.9% of *E. cloacae* (ECL) at ≤4 µg/mL. CAZ-AVI MIC~50/90~ for these species were 0.06/0.12, 0.12/0.25, 0.12/0.5 µg/mL, respectively (Table) whereas CAZ MIC~90~ values were 2, 32 and \>32 µg/mL, respectively. All but one *P. mirabilis* were inhibited by CAZ-AVI at ≤0.5 µg/mL. 214 KPC-producers, 497 CTX-M-15-like and 102 CTX-M-14-like strains were identified and CAZ-AVI MIC~50/90~ values for these strains were 0.5/2, 0.12/0.5 and 0.12/0.25 µg/mL, respectively. KPC-producers were very resistant to all comparators with CAZ-AVI, tigecycline (MIC~50/90~, 0.5/1 µg/mL) and colistin (MIC~50/90~, 0.5/2 µg/mL) being the only agents with acceptable coverage.

  Organisms/Group (no. tested)    CAZ-AVI MIC (µg/mL):   
  ------------------------------- ---------------------- ------
  All (20,709)                    0.12                   0.25
  *E. coli* (6,486)               0.06                   0.12
  *K. pneumoniae* (4,421)         0.12                   0.25
  *E. cloacae* (2,261)            0.12                   0.5
  *P. mirabilis* (1,626)          ≤0.03                  0.06
  KPC-producers (214)             0.5                    2
  CTX-M-15-like-producers (497)   0.12                   0.5
  CTX-M-14-like-producers (102)   0.12                   0.25

***Conclusion.*** CAZ-AVI displayed high activity against contemporary ENT isolates, including those producing prevalent CTX-M-variants in the USA, and KPC-producers that are often MDR.
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